Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors

Cancer Immunology, Immunotherapy

Volumn 55, Issue 8, 2006, Pages 933-947

  Bundell, Christine S ^a   Jackaman, Connie ^a   Suhrbier, Andreas ^d   Robinson, Bruce W S ^a,c   Nelson, Delia J ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CURTIN UNIVERSITY   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Antigens peptides epitopes; Cytotoxic; T cells; Tumor Immunity

Indexed keywords

EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DRUG POTENCY; EFFECTOR CELL; ERADICATION THERAPY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR REGRESSION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; OVALBUMIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 33646379151     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0086-6     Document Type: Article

References (59)

1. Ridgway D (2003) The first 1000 dendritic cell vaccinees. Cancer Invest 21(6):873
2. Stoler DL, Chen N, Basik M, Kahlenberg MS, Rodriguez-Bigas MA, Petrelli NJ, Anderson GR (1999) The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc Natl Acad Sci USA 96(26):15121
3. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, Sugimachi K, Mori M (2001) Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 85(5):713
4. Vandeneynde BJ, Vanderbruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9(5):684
5. Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50(1):3
6. Ioannides CG, Freedman RS, Platsoucas CD, Rashed S, Kim YP (1991) Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. J Immunol 146(5):1700
7. Eifuku R, Yoshino II, Imahayashi S, Fujie H, Takenoyama M, Yoshimatsu T, Hanagiri T, So T, Ichiyoshi Y, Nomoto K, Yasumoto K (1998) Induction of tumor-specific cytotoxic T lymphocytes from regional lymph node lymphocytes of human breast cancer. Breast Cancer 5(4):367
8. Van den Eynde B, Hainaut P, Herin M, Knuth A, Lemoine C, Weynants P, van der Bruggen P, Fauchet R, Boon T (1989) Presence on a human melanoma of multiple antigens recognized by autologous CTL. Int J Cancer 44(4):634
9. Johnston JV, Malacko AR, Mizuno MT, McGowan P, Hellstrom I, Hellstrom KE, Marquardt H, Chen L (1996) B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J Exp Med 183(3):791
10. Yewdell JW, Bennink JR (1999) Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17:51
11. Chen W, Anton LC, Bennink JR, Yewdell JW (2000) Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12(1):83
12. Flynn KJ, Belz GT, Altman JD, Ahmed R, Woodland DL, Doherty PC (1998) Virus-specific CD8+ T cells in primary and secondary influenza pneumonia. Immunity 8(6):683
13. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G (1993) Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today 14(5):203
14. Voskuhl RR, Farris RW II, Nagasato K, McFarland HF, Dalcq MD (1996) Epitope spreading occurs in active but not passive EAE induced by myelin basic protein. J Neuroimmunol 70(2):103
15. Newmaster RS, Mylin LM, Fu TM, Tevethia SS (1998) Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection. Virology 244(2):427
16. Pilon SA, Kelly C, Wei WZ (2003) Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J Immunol 170(3):1202
17. Feltkamp MC, Vreugdenhil GR, Vierboom MP, Ras E, van der Burg SH, ter Schegget J, Melief CJ, Kast WM (1995) Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol 25(9):2638
18. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20(11):2624
19. Ranieri E, Kierstead LS, Zarour H, Kirkwood JM, Lotze MT, Whiteside T, Storkus WJ (2000) Dendritic cell/peptide cancer vaccines: clinical responsiveness and epitope spreading. Immunol Invest 29(2):121
20. el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29(10):3295
21. Anderson BW, Kudelka AP, Honda T, Pollack MS, Gershenson DM, Gillogly MA, Murray JL, Ioannides CG (2000) Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol Immunother 49(9):459
22. Tatsumi T, Gambotto A, Robbins PD, Storkus WJ (2002) Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. Cancer Res 62(20):5853
23. Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF (2001) Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int Immunol 13(5):625
24. Liau LM, Jensen ER, Kremen TJ, Odesa SK, Sykes SN, Soung MC, Miller JF, Bronstein JM (2002) Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res 62(8):2287
25. Lally KM, Mocellin S, Ohnmacht GA, Nielsen MB, Bettinotti M, Panelli MC, Monsurro V, Marincola FM (2001) Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int J Cancer 93(6):841
26. Lipford GB, Hoffman M, Wagner H, Heeg K (1993) Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif. J Immunol 150(4):1212
27. Sandberg JK, Grufman P, Wolpert EZ, Franksson L, Chambers BJ, Karre K (1998) Superdominance among immunodominant H-2Kb-restricted epitopes and reversal by dendritic cell-mediated antigen delivery. J Immunol 160(7):3163
28. Nelson DJ, Mukherjee S, Bundell C, Fisher S, van Hagen D, Robinson B (2001) Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J Immunol 166(9):5557
29. Marzo AL, Lake RA, Robinson BW, Scott B (1999) T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59(5):1071
30. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ (2003) IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol 171(10):5051
31. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR (1994) T cell receptor antagonist peptides induce positive selection. Cell 76(1):17
32. Moore MW, Carbone FR, Bevan MJ (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54(6):777
33. Boyle JS, Koniaras C, Lew AM (1997) Influence of cellular location of expressed antigen on the efficacy of DNA vaccination: cytotoxic T lymphocyte and antibody responses are suboptimal when antigen is cytoplasmic after intramuscular DNA immunization. Int Immunol 9(12):1897
34. Nishimura A, Morita M, Nishimura Y, Sugino Y (1990) A rapid and highly efficient method for preparation of competent Escherichia coli cells. Nucleic Acids Res 18(20):6169
35. Lyons AB, Parish CR (1994) Determination of lymphocyte division by flow cytometry. J Immunol Methods 171(1):131
36. Oehen S, Brduscha-Riem K (1998) Differentiation of naive CTL to effector and memory ctl: correlation of effector function with phenotype and cell division. J Immunol 161(10):5338
37. Nelson D, Bundell C, Robinson B (2000) In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes. J Immunol 165(11):6123
38. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J (1994) Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues. J Exp Med 180(4):1471
39. Le TT, Drane D, Malliaros J, Cox JC, Rothel L, Pearse M, Woodberry T, Gardner J, Suhrbier A (2001) Cytotoxic T cell polyepitope vaccines delivered by ISCOMs. Vaccine 19(32):4669
40. Schirmbeck R, Fissolo N, Chaplin P, Reimann J (2003) Enhanced priming of multispecific, murine CD8+ T cell responses by DNA vaccines expressing stress protein-binding polytope peptides. J Immunol 171(3):1240
41. Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, Gudkov AV (2002) Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene 21(1):153
42. Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS (1999) Generation of Human T-cell Responses to an HLA-A2.1-restricted peptide epitope derived from alpha-Fetoprotein. Cancer Res 59(13):3134
43. Chen L, Mizuno M, Singhal M, Hu S, Galloway D, Hellstrom I, Hellstrom K (1992) Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol 148(8):2617
44. Thornburg C, Boczkowski D, Gilboa E, Nair SK (2000) Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. J Immunother 23(4):412
45. Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, Robinson BW, Scott B (1999) Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 162(10):5838
46. Thomson SA, Elliott SL, Sherritt MA, Sproat KW, Coupar BE, Scalzo AA, Forbes CA, Ladhams AM, Mo XY, Tripp RA, Doherty PC, Moss DJ, Suhrbier A (1996) Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol 157(2):822
47. Mateo L, Gardner J, Chen Q, Schmidt C, Down M, Elliott SL, Pye SJ, Firat H, Lemonnier FA, Cebon J, Suhrbier A (1999) An HLA-A2 polyepitope vaccine for melanoma immunotherapy. J Immunol 163(7):4058
48. Thomson SA, Sherritt MA, Medveczky J, Elliott SL, Moss DJ, Fernando GJ, Brown LE, Suhrbier A (1998) Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol 160(4):1717
49. Anraku I, Harvey TJ, Linedale R, Gardner J, Harrich D, Suhrbier A, Khromykh AA (2002) Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity. J Virol 76(8):3791
50. Kawakami Y, Dang N, Wang X, Tupesis J, Robbins PF, Wang RF, Wunderlich JR, Yannelli JR, Rosenberg SA (2000) Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother 23(1):17
51. Evans E, Man S, Evans A, Borysiewicz L (1997) Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes. Cancer Res 57(14):2943
52. Robinson BW, Robinson C, Lake RA (2001) Localised spontaneous regression in mesothelioma - possible immunological mechanism. Lung Cancer 32(2):197
53. Folkman J, Kalluri R (2004) Cancer without disease. Nature 427(6977):787
54. Knutson KL, Disis ML (2005) Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 54(8):721-728
55. Weber J, Sondak VK, Scotland R, Phillip R, Wang F, Rubio V, Stuge TB, Groshen SG, Gee C, Jeffery GG, Sian S, Lee PP (2003) Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97(1):186
56. Chiong B, Wong R, Lee P, Delto J, Scotland R, Lau R, Weber J (2004) Characterization of long-term effector-memory T-cell responses in patients with resected high-risk melanoma receiving a melanoma peptide vaccine. J Immunother 27(5):368
57. el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L (1999) MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol 29(10):3295
58. Lehmann F, Marchand M, Hainaut P, Pouillart P, Sastre X, Ikeda H, Boon T, Coulie PG (1995) Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 25(2):340
59. Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A (2003) Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171(9):4893